Skip to content

EDX Medical Group - Posting of notice of General Meeting


Announcement provided by

EDX Medical Group Plc · EDX

17/06/2025 07:00

EDX Medical Group - Posting of notice of General Meeting
RNS Number : 0500N
EDX Medical Group PLC
17 June 2025
 

 

 

 

EDX Medical Group plc: EDX

17 June 2025

 

A blue hexagon with white x and blue x Description automatically generated with low confidence

17 June 2025

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Group" or "Company")

Posting of Notice of General Meeting

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces that a general meeting will be held at the Heritage Centre, Royal School of Medicine, 2nd floor, 1 Wimpole St, Westminster, London, W1G 0AE on 3 July at 11am.

The Notice of General Meeting and Form of Proxy will be posted today, 17 June 2025, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/

Contacts:

 

EDX Medical Group plc



Dr Mike Hudson (Chief Executive Officer)

+44 (0)7812 345 301





Oberon Capital



Nick Lovering (Corporate Adviser)

Adam Pollock (Corporate Broking)

Mike Seabrook (Corporate Broking)

+44 (0)20 3179 5300





IFC Advisory (Investor Relations)


Tim Metcalfe

+44 (0)20 3934 6630

Graham Herring






Media House International



Ramsay Smith

 

Gary McQueen

+44 (0)7788 414856

ramsay@mediahouse.co.uk

+ 44 (0)7834 694609

gary@mediahouse.co.uk

 

Notes for Editors:

About EDX Medical Group

EDX Medical Group Plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXSFDFLMEISEIM]]>

View more ...

EDX announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2025. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal